Evommune, Inc. (EVMN)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$12.27+2.25%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · EVMN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -83.2% |
| Our one-year growth estimate | diamond | -83.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 0.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
EVMN — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the second quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Secti…
Why it matters: Revenue performance will show if the company can meet its $13 million target for 2026.
Worry ifRevenue for 2026 shows significant growth towards the $13 million target.
Less concerning ifRevenue stays at zero or goes down. This shows it did not meet guidance.
Why it matters: Starting this trial signals Evommune's commitment to expanding EVO756's use. Success could lead to new revenue streams.
Supportive ifThe trial begins with patient dosing and enrollment confirmed.
Worry ifThe trial is delayed or not initiated as planned.
Why it matters: The company set a revenue target of $13 million for 2026. Q2 results will show progress.
Watch forQ2 revenue was over $3 million. This shows progress toward the $13 million goal.
Also watch forQ2 revenue remains at zero or declines, showing no progress.
Why it matters: Updates on this trial will show progress in creating a new migraine treatment.
Supportive ifTop-line data shows a significant reduction in monthly migraine days for patients in the trial.
Worry ifTrial results show no significant reduction in monthly migraine days.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$273 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $1,083 loss on $10,000 · 10.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,500 loss on $10,000 · 65.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The success of this trial could open a new market for EVO756. It indicates the drug's versatility in treating different conditions.
Watch forTop-line data shows a big drop in monthly migraine days (MMD) in patients.
Also watch forData shows no big drop in MMD compared to the starting point.
Why it matters: Results will show if the company can grow its product pipeline.
Watch forThe Phase 2 trial for other indications shows positive results.
Also watch forThe Phase 2 trial for other indications shows negative results.
Why it matters: If revenue growth picks up, it could improve the outlook for Evommune.
Supportive ifHealth Care sector revenue growth accelerates back toward 10% or higher.
Worry ifRevenue growth is slowing down and is below 10%.
Why it matters: The data will show if the treatment is effective. This is key for future trials.
Supportive ifThe Phase 2b trial for Atopic Dermatitis shows positive results.
Worry ifThe Phase 2b trial for Atopic Dermatitis shows negative results.
Why it matters: Good results could help EVO301's Phase 2b trial for treating atopic dermatitis.
Supportive ifFull results show big gains in key secondary goals for atopic dermatitis.
Worry ifFull results show no big gains in key secondary goals.
Why it matters: This data will show if EVO756 can treat atopic dermatitis after failing in CSU. A good result could help further development.
Supportive ifData from the Phase 2b trial shows a big improvement in the Urticaria Activity Score.
Worry ifData shows no major change in the Urticaria Activity Score.
Why it matters: Starting this trial in mid-2027 is important for more treatment options in atopic dermatitis. It may support the company's plans.
Supportive ifAnnouncement of the start of the Phase 2b trial for EVO301 in atopic dermatitis.
Worry ifDelay in starting the Phase 2b trial or cancellation of the trial.
Why it matters: Top-line data will show if EVO756 can help patients with atopic dermatitis. This data is key for future development.
Supportive ifData shows at least a 50% drop in Eczema Area and Severity Index (EASI) at Week 12.
Worry ifTop-line data shows less than a 50% reduction in EASI at Week 12.
Why it matters: Updates on cash reserves will show if Evommune can keep its development plans going.
Supportive ifCash reserves are above $288 million, showing strong financial health.
Worry ifCash reserves are below $200 million. This raises worries about funding.